

**CORRELATION BETWEEN DNA PLOIDY AND PS2 IN
BREAST CANCER**

Thesis


Submitted For Partial Fulfillment Of

Ph.D. Degree In Biochemistry

By

Maha Imam Ahmed

M.Sc. Biochemistry



616.99249

H. I


Supervisors

Prof. Nawal Abdou Zeiada

**Professor and Head of
Biochemistry Department
Faculty of Medicine
Ain Shams University**

Prof. Ali Khalifa Ali

**Professor of Biochemistry
Head of Oncology
Diagnostic Unit
Faculty of Medicine
Ain Shams University**



Dr. Thanaa El-Sayed Helal

**Ass. Professor of Pathology
Faculty of Medicine
Ain Shams University**

Dr. Sanaa Eissa Hamed

**Lecturer of Biochemistry
Faculty of Medicine
Ain Shams University**

Faculty of Medicine

Ain Shams University

1994



رَبِّهِمُ اللَّهُ الرَّحْمَنُ الرَّحِيمُ
قَالُوا

سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا عَلَّمْتَنَا
إِنَّا أَنْتَ الْعَلِيمُ الْحَكِيمُ

صَدَقَ اللَّهُ الْعَظِيمُ

سورة البقرة آية ٢٢



Approval Sheet

Prof. Dr. Ahmad S. Fayth-Allah

A. S. Fayth-Allah

Prof. Dr. Nawal A. Zeyada

Dr. Nawal Zeyada

Prof. Dr. Mofida M. Salah

Mofida M. Salah

Prof. Dr. Ali Khalifa Ali

Ali Khalifa Ali



ACKNOWLEDGEMENTS

First and foremost thanks to God.

I would like to extend, cordial appreciation and infinite gratitude to Prof. Nawal Abdou Zeiada Professor and Head of Biochemistry Department, Ain Shams Faculty of Medicine, for her motherly guidance and advice. She spared no effort to help me along the entire course of the work.

My words fail me to express my deepest appreciation to Prof. Ali Khalifa, Professor and Head of Oncology Diagnostic Unit, Biochemistry Department, Ain Shams Faculty of Medicine. He has been, as he always is, most helpful to me throughout the whole work. His continual watchfulness, his invaluable counsel and most creative and instructive ideas and thoughts have motivated my energy. His endurance has pushed me ahead, and have endowed me with hope, patience and perseverance.

I am deeply grateful to my tutor Dr. Sanaa Eissa, Lecturer of Biochemistry, Ain Shams Faculty of Medicine. She gave time unselfishly and shared in the objective and critical evaluation of the text. I extend very special thanks to her for sharing ideas and making recommendations to improve the work and for cooperating throughout the period of preparation. She carefully read and reviewed every part of the manuscript, making many excellent suggestions and corrections.

I am so grateful to Dr. Thanana Helal, Assistant Professor of Pathology, Ain Shams Faculty of Medicine for her scientific guidance and valuable assistance.

I am also very grateful to Dr. Sohir sayed Ismail, Assistant Professor of Radiotherapy, Ain Shams Faculty of Medicine.

Finally, very special thanks are due to a supportive and considerate family, particularly to my husband to my parents and to both my father and mother-in-law.

CONTENTS

	<i>Page</i>
• Introduction and aim of work	1
• Review of literature	3
••Breast cancer.	3
••Biology of breast cancer.	15
••Prognostic factors in breast cancer.	18
••Estrogen receptors.	24
••Progesterone receptors.	29
••PS2 protein.	33
••Flowcytometry :	39
- Clinical FCM instrumentation.	39
- Clinical applications of FCM.	44
- DNA content as a genetic marker of cancer cells.	52
- Cell cycle.	58
- Methodology of DNA analysis by FCM.	62
- FCM and breast cancer.	70
• Patients and Methods	75
•• Patients.	75
•• Estimation of cytosolic total proteins.	79

	<i>Page</i>
.. Estimation of cytosolic ER.	81
.. Estimation of cytosolic PGR.	87
.. Estimation of cytosolic PS2.	90
.. DNA analysis by FCM.	94
.. Statistical analysis.	103
• Results	104
• Dissecution.	159
• Summary and conclusions.	185
• References.	186
• Appendix.	
• Arabic summary.	

LIST OF TABLES

	<i>Page</i>
1: DNA ploidy in human cells.	56
2: Clinical and Histopathological Findings of Benign and Malignant Groups	76
3: Tumor Size in Relation to Other Clinical and Histopathological Findings.	109
4: Lymph Node Status in Relation to Other Clinical and Histopathological findings.	113
5: Number of Positive Lymph Nodes in Relation to Other Clinical and Histopathological Findings.	115
6: Tumor Grade in Relation to Other Clinical and Histopathological Findings.	116
7: Clinical Stage in Relation to Other Clinical and Histopathological Findings.	118
8: Tumor Type in Relation to Other Clinical and Histopathological Findings.	119
9: Mean Values of Investigated Parameters in Benign and Malignant Groups.	120
10: The Positivity Rate of Investigated Parameters in Benign and Malignant Groups.	122

	<i>Page</i>
11: Mean Values and Positivity Rate of ER in Relation to other Clinical and Histopathological Findings (in malignant group).	124
12: Mean Values and Positivity Rate of PGR in Relation to other Clinical and Histopathological Findings in malignant tumors.	128
13: Mean Values and Positivity Rate of PS2 in Relation to other Clinical and Histopathological Findings in Malignant Tumors.	130
14: Relation Between DNA Ploidy and Clinical and Histopathological Findings in Malignant Tumors.	141
15: Mean Values of DI and Positivity Rate in Relation to other Clinical and Histopathological Findings in Malignant Tumors	144
16: Mean % SPF and Positivity rate (Cut: 10%,20%) in Relation to other Clinical and Histopathological Findings in Malignant Tumors .	150
17: Correlation Between the Positivity Rate of Different Investigated Parameters in Malignant Tumors.	153
18: Correlation coefficients of different investigated quantitative parameters in the malignant group.	158

LIST OF FIGURES

	<i>Page</i>
1-a: Mechanism of action of steroid hormones .	27
1-b: Model of estrogen receptor action.	27
2: Schematic diagram of a flow cytometer.	40
3: Schematic diagram of a flow cell.	43
4: Schematic diagram of a photomultiplier tube.	43
5-a: DNA aneuploid population.	55
5-b: DNA diploid poulation.	55
6: Mathematical methods for SPF approximation.	57
7: Relationship between changes in DNA content through the cell cycle and the frequency distribution curve of DNA content.	59
8-a: Comparison of peak and integral pulses.	71
8-b: Histogram gating to exclude doublets.	71
9: Protein standard curve.	82
10: ER standard curve.	86
11: PGR standard curve.	91
12: PS2 standard curve.	95
13: Correlation between tumor size and clinical stage.	110
14: Correlation between tumor size and lymph node status.	111
15: Correlation between tumor size and relapse.	112
16: Correlation between lymph node status and clinical stage.	114

	<i>Page</i>
17: Correlation between tumor size and tumor grade.	117
18: Mean values of investigated parameters in benign and malignant groups.	121
19: Positivity rate of investigated parameters in benign and malignant groups.	123
20: Correlation between ER status and tumor size.	125
21: Correlation between ER status and clinical stage.	126
22: Correlation between ER and recurrence in ANP tumors.	127
23: Correlation between PGR and recurrence in ANN tumors.	129
24: Correlation between PS2 and tumor size.	131
25: Correlation between PS2 and relapse in ANN tumors.	132
26: Correlation between PS2 and relapse in ANP tumors.	133
27: Ploidy pattern in benign and malignant tumors.	134
28: Ploidy pattern in malignant tumors.	135
29: DNA diploid pattern.	136
30: DNA aneuploid pattern.	137
31: DNA multiploid pattern.	138
32: DNA hypertetraploid pattern.	139
33: DNA tetraploid pattern.	140
34: DI frequency distribution curve in malignant tumors.	142
35: DI frequency distribution curve in benign tumors.	143
36: Correlation between DI and lymph node status.	145
37: Correlation between DI and histologic grade.	146

	<i>Page</i>
38: Correlation between DI and relapse in ANP tumors.	147
39: Correlation between DNA ploidy and lymph node status.	148
40: Correlation between DNA and No of positive lymphnodes.	149
41: Correlation between SPF and tumor size.	151
42: Correlation between ER and PGR.	152
43: Correlation between SPF and ploidy status.	154
44: Correlation between ER and PGR.	155
45: Correlation between ER and PS2.	156
46: Correlation between PGR and PS2.	157

LIST OF ABBREVIATIONS

AJCC	:	American joint committee for cancer.
ANN	:	Axillary node negative.
ANP	:	Axillary node positive.
AT	:	Adenine thymine.
BCEI	:	Breast cancer estrogen induced gene.
Cath.D	:	Cathepsin D.
C-erb-B2	:	Oncogene from erythroblastosis virus.
CV	:	Coeffecient of variation.
DCIS	:	Ductal carcinoma in situ.
DFS	:	Disease free survival.
DI	:	DNA index.
DNA	:	Deoxy ribonucleic acid.
EGFR	:	Epidermal growth factor receptor.
EIA	:	Enzyme-immunoassay.
ER+	:	Estrogen receptor positive.
FCM	:	Flowcytometry.
GC	:	Guanine cytosine.
HER2	:	Human epidermal growth factor receptor related gene.
HIV	:	Human immunodeficiency virus.
HSP	:	Heat shock protein.
ICA	:	Immunocytochemical assay.
IDC	:	Invasive duct carcinoma.

IGFs	:	Insulin growth factors.
ILC	:	Invasive lobular carcinomas.
LCIS	:	Lobular carcinoma in situ.
LPR	:	Lysing permeabilizing reagent.
MAB	:	Monoclonal antibodies.
neu	:	Neuroblastoma oncogene.
nm 23	:	nonmetastatic 23 gene.
OS	:	Overall survival.
p53	:	Protein 53.
PCNA	:	Proliferating cell nuclear antigen.
PDGF	:	Platelet derived growth factor.
PGR+	:	Progesterone receptor positive.
PMTs	:	Photomultiplier tubes.
PS2	:	Protein S2.
RB	:	Retinoblastoma gene.
RBCs	:	Red blood cells.
RIA	:	Radioimmunoassay.
RNA	:	Ribonucleic acid.
SPF	:	Synthetic phase fraction.
TGF-α	:	Transforming growth factor-alpha.
TGF-β	:	Transforming growth factor-beta.
TNM	:	T (tumor), N (lumph node), M (distant metastases).
+,+ve	:	Positive.
-, -ve	:	Negative.